$NVDA he couldn’t keep his pants on, I expect Burry to print soon.
Zeev Bovan
Posts (679)
“We believe the expanded derm sales effort, new PCP/peds team, and telehealth platform provide the key levers for Zoryve to continue its growth momentum into 2027,” Belanger wrote, maintaining his Buy rating and $40 target.
Jefferies analyst Andrew Tsai agreed. Strong underlying demand, helped by a 30-person PCP/PED salesforce and a new Simone Biles-led DTC campaign, should drive TRx volumes higher in early 2027,” Tsai wrote with his Buy rating and $39 target unchanged.
Buy the dip fools
That’s how Wall Street makes money, some one yells boo and the retail shake thier boots and run and they buy it cheap.
Holy moly… that’s a nose dive
Pslantir will become a1000$ plus stock but it will take along nerve wrecking time, like an over inflated balloon it will loose air and gain air till the company generate enough profits to justify the insane pe.
Wait for the pipe lines and facilities that would be required, $BKR will triple or at least double.
Going back where it belongs, around 24$, don’t invest in ballon’s, it’s ok to play poker from time to time but if you are playing it for few years and you still don’t know who is the shark and who is the fish you are the fish.
$TARA will pull a Sandisk move eventually
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics
October 15, 2026 08:00 ET